Trevi Therapeutics (NASDAQ:TRVI) Earns Outperform Rating from Analysts at Leerink Partners
Leerink Partners began coverage on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a research report released on Monday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $7.00 price objective on the stock. Other research analysts also recently issued research reports about the company. Rodman & Renshaw began coverage on Trevi […]
More Stories
SPDR Bloomberg Barclays International Treasury Bond ETF (NYSEARCA:BWX) Sees Large Volume Increase – Time to Buy?
SPDR Bloomberg Barclays International Treasury Bond ETF (NYSEARCA:BWX – Get Free Report) shares saw unusually-strong trading volume on Monday ....
LandBridge (NYSE:LB) Shares Down 9% – Time to Sell?
LandBridge Co LLC (NYSE:LB – Get Free Report) traded down 9% on Monday . The company traded as low as...
Short Interest in Tessenderlo Group NV (OTCMKTS:TSDOF) Drops By 70.0%
Tessenderlo Group NV (OTCMKTS:TSDOF – Get Free Report) was the target of a large decrease in short interest in December....
Invesco National AMT-Free Municipal Bond ETF (NYSEARCA:PZA) Sees Large Volume Increase – Still a Buy?
Invesco National AMT-Free Municipal Bond ETF (NYSEARCA:PZA – Get Free Report) shares saw unusually-strong trading volume on Monday . Approximately...
Tertiary Minerals (LON:TYM) Sets New 12-Month Low – Time to Sell?
Tertiary Minerals plc (LON:TYM – Get Free Report) reached a new 52-week low during mid-day trading on Monday . The...
Plato Gold (CVE:PGC) Sets New 12-Month High – Still a Buy?
Plato Gold Corp. (CVE:PGC – Get Free Report)’s stock price reached a new 52-week high during trading on Monday ....